Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies

Authors, Journal, Affiliations, Type, DOI

• Authors: Aggarwal A, Stolear A, Alam MM, Vardhan S, Dulgher M, Jang S-J, Zarich SW
• Journal: Journal of Clinical Medicine (MDPI), 2024;13(6):1781
• Affiliations: Yale New Haven Health / Bridgeport Hospital; Yale University School of Medicine; Nuvance Health / Norwalk Hospital
• Type: Narrative review
• DOI: https://doi.org/10.3390/jcm13061781

Overview

Comprehensive 2024 narrative review of CPVT covering history, epidemiology, genetics, pathophysiology, diagnosis, prognosis/risk stratification, and the full spectrum of therapeutic interventions. The management section reflects a contemporary paradigm shift: ICD is now a last resort reserved for cases where triple therapy (nadolol + flecainide + LCSD) has failed, supported by international registry data showing worse outcomes in ICD recipients attributable to ICD proarrhythmia. The Giudicessi diagnostic scorecard is presented as a novel pre-test probability tool for CPVT that can reduce the RyR2 VUS rate from 48% to 7%. Gene therapy strategies (CASQ2 AAV replacement, allele-specific RNAi, CRISPR/Cas9) and iPSC-CM platforms are reviewed as future frontiers with outstanding immune response challenges.

Keywords

Catecholaminergic polymorphic ventricular tachycardia; arrhythmias; sudden cardiac death; beta-blockers; flecainide; left cardiac sympathetic denervation; gene therapy; electrophysiology; precision medicine

Key Takeaways

§2. History

• First CPVT description: Berg 1960 — three sisters with exercise/emotional syncope
• Bidirectional VT association noted: 1975 (Reid et al.)
• Term "CPVT" coined: 1978 (Coumel et al.)
• First genetic locus (chromosome 1q42-q43): 1999 (Swan et al.)
• RYR2 identified as causal gene: 2001 (Priori et al.)

§3. Epidemiology

• Prevalence ~1:10,000; responsible for up to 15% of unexplained SCD in young people (<35 years)
• Mean age of symptom onset 7–12 years; >60% experience first syncope/CA by age 20; atypical late-onset cases (3rd–4th decade) recognised
• ~30% of CPVT patients have family history of stress-related syncope/seizure/SCD in relatives <40 years; up to 60% in RYR2 families
• Males present younger (childhood/adolescence); females present later (~age 20 average)
• Mortality: 30–50% by age 35 if unrecognised and untreated; 12% of autopsy-negative SUD in young linked to CPVT; some SIDS cases attributed to CPVT

§4. Clinical Presentation

• Most common initial presentation: exertional/emotional syncope; ~1/3 of VT episodes degenerate to VF → SCD
• Frequently misdiagnosed as vasovagal syncope or epilepsy (seizure-like activity during syncope)
• Average time from first symptom to diagnosis: 2 ± 0.8 years

§5. Genetics and Pathophysiology

• RYR2 (CPVT1): 60–70%; AD; GOF missense variants 96%; hotspot regions: exons 3–15, 44–50, 83–90, 93–105
• CASQ2 (CPVT2): 2–5%; AR; calcium buffering LOF
• TECRL (CPVT3): <1%; AR; overlap CPVT/LQTS phenotype
• CALM1 (CPVT4): <1%; AD
• TRDN (CPVT5): <1%; AR; triadin LOF
• CALM3 (CPVT6): <1%; AD
• CASQ2 variants: novel neurological manifestations recently identified
• Penetrance: overall 63–78%; RYR2 75–80%; biallelic CASQ2 100%
• De novo RYR2 variants: majority of monogenetic RYR2 cases; earlier onset and more severe phenotype than familial forms
• CNV analysis: RYR2 deletion frequencies 1.9–8.3%; comprehensive SNV+indel+CNV analysis may raise diagnostic yield from 60–65% to 70%
• Genetic testing recommended for all CPVT-susceptibility genes (RYR2, CASQ2, CALM1-3, TRDN, TECRL) in all probands and first-degree relatives with a P/LP variant

§6. Diagnosis

• HRS consensus diagnostic criteria (4 criteria):
  1. Structurally normal heart, normal ECG + unexplained exercise/catecholamine-induced bidirectional VT or polymorphic PVCs in patient <40 years
  2. Pathogenic mutation in patient (index or family member)
  3. Family member of CPVT index case with normal heart manifesting exercise-induced PVCs or bidirectional/polymorphic VT
  4. Can be diagnosed >40 years with structurally normal heart, coronary arteries, normal ECG + unexplained exercise/catecholamine-induced bidirectional VT or polymorphic PVCs
• PVC features distinguishing CPVT from controls: late-coupled PVCs; LBBB pattern + inferior axis (most sensitive/specific — suggests RVOT as origin in paediatric CPVT); larger PVC burden; first appearance at higher workload; bigeminy/trigeminy at peak stress; QRS >120 ms; coupling interval >400 ms; disappearance in first minute of recovery
• Cardiopulmonary exercise testing (CPET): VAT (ventilatory anaerobic threshold) consistently precedes onset of ventricular ectopy at higher heart rates — suggests metabolic shift to anaerobic metabolism contributes to arrhythmogenesis
• Epinephrine infusion: 0.05–0.1 mcg/kg/min, increments of 0.05 mcg/kg/min, max 0.20 mcg/kg/min; positive = >10 PVCs/min or new T-wave alternans; sensitivity 28%, specificity 98% (lower than exercise testing)
• Holter: Alternative when exercise testing unfeasible (e.g., very young); generally less sensitive than exercise testing

Giudicessi Diagnostic Scorecard

Novel pre-test probability tool for CPVT1 (RyR2-mediated CPVT). Integrates:

• Symptoms: Exercise/activity-associated ACA/SCA = 2 pts; syncope/seizures = 1 pt
• Exercise/Holter findings (requires ≥1 finding): Bidirectional VT at HR >100 bpm = 4 pts; PVCs in bigeminy + bidirectional couplets at HR >100 bpm = 2 pts; PVCs at HR >100 bpm = 1 pt
• QTc: ≤420 ms = +0.5; 421–459 = 0; ≥460 ms = −0.5
• Genetic test: Pathogenic = +4; likely pathogenic = +2; VUS = 0; negative RYR2/CASQ2/TRDN/CALM1-3 = −1
• Holter: Ambulatory ectopy >2% of beats = −1
• Imaging: Evidence of ischemic/structural disease = −2
• Age: ≥50 at sentinel event = −1
• Family history: 1st-degree relative with definite CPVT = +1.5; suspicious autopsy-negative SCD (exertional/near-drowning) in 1st/2nd-degree relative ≤45 = +1; unexplained autopsy-negative SCD 1st/2nd-degree relative ≤45 = +0.5
• Interpretation: ≥3.5 pts = definite/probable CPVT (≥90% likelihood); 2–3 pts = possible CPVT (~50%); 0.5–1.5 = nondiagnostic; ≤0 = no CPVT
• Clinical utility: Reduces RyR2 VUS misclassification rate from 48% to 7% by integrating clinical phenotype into variant adjudication

§7. Prognosis and Risk Stratification

• Average time from first symptom to diagnosis: 2 ± 0.8 years
• 30% have had ≥1 cardiac arrest prior to diagnosis; up to 80% have had ≥1 syncopal episode
• Independent predictors of adverse cardiac events: younger age at diagnosis, proband status, multiple genetic variants, AR inheritance, history of prior ACA, absence of BB therapy or incomplete symptom suppression despite pharmacological treatment
• Early repolarization pattern (ERP) on ECG associated with increased symptomatic presentation
• No genetic modifiers influencing CPVT event risk identified to date
• Detection of NSVT during exercise testing linked to worse outcomes; however, some arrests occur in patients with no arrhythmias on stress testing
• PES not valuable for risk stratification (rare inducible arrhythmias)

§8. Therapeutic Strategies

§8.1 Lifestyle Modifications

• Competitive and intensive leisure-time sports strongly discouraged (ESC/EAPC/EHRA position statement)
• Low-to-moderate leisure-time sports permissible if asymptomatic ≥3 months and stress tests show no ventricular ectopy/arrhythmia (including those with ICD)
• Gene carriers without overt symptoms managed same as manifest CPVT — low-intensity sports only
• Avoid stressful situations, dehydration, electrolyte disturbances, hyperthermia
• Follow-up includes stress tests and/or Holter during low-intensity activities

§8.2 Beta-Blockers

• Lifelong non-selective BB without intrinsic sympathomimetic activity: unequivocal therapeutic foundation
• Nadolol preferred: 1–2 mg/kg/day; HR 2.04 (p=0.002) for BB1-selective vs nadolol in symptomatic children (Ishibashi et al.); HR 5.8 (p=0.001) for BB1-selective vs nadolol in 216 RYR2-variant cohort (multinational study); no significant difference between nadolol and propranolol
• Propranolol as alternative when nadolol unavailable
• Class Ic recommendation for symptomatic patients; Class IIa for asymptomatic genotype-positive phenotype-negative patients
• Non-adherence: 15% of patients non-adherent in international CPVT cohort; female sex, concerns about medication, and flecainide monotherapy were independently associated with non-adherence; 60% of evening-hour cardiac events attributed to non-adherence
• BB-free strategy: 10% of patients in international CPVT registry require BB-free approach (side effects); viable for asymptomatic patients with absent or negligible stress test phenotype (no bigeminy, couplets, or complex ectopy) — requires careful risk assessment; not for routine use

§8.2.2 Flecainide

• Indicated for breakthrough despite optimal BB (up to 30% of patients)
• ESC dosing: 2–3 mg/kg/day; conventional total daily dose 100–300 mg
• Only randomized trial: 14-patient crossover (protocol-modified to secondary endpoint of exercise-induced VA; no VT/couplets/NSVT during exercise in flecainide group); demonstrates superiority over maximally tolerated BB alone
• Multinational retrospective cohort (247 patients): adjunctive flecainide + BB showed significant reduction in arrhythmic events (SCD, SCA, appropriate ICD shocks, arrhythmic syncope); consistent across full cohort, symptomatic patients, and breakthrough-on-BB subgroup
• Flecainide monotherapy documented in select cases but less robust than combination therapy
• Mechanism remains debated: RyR2 blockade (Hilliard 2010, Kryshtal 2021) vs Na+ channel only (Liu 2011) vs no direct RyR2 effect (Bannister 2016)

§8.2.3 Other Medications

• Propafenone (class IC): Limited application in CPVT; evidence from case reports only; no primary investigative research
• Verapamil: Preliminary small-scale studies showed cautious optimism; extended follow-up data demonstrated no significant benefit — rarely used in practice
• Ivabradine (HCN blocker): Sporadically tested with nadolol or flecainide; well-tolerated. Animal models showed no reduction in DADs or delayed VAs in mouse model → should not be considered a CPVT treatment
• Dantrolene (RYR1/RYR2 blocker): Attenuates abnormal Ca²⁺ handling in animal CPVT models; no human studies; theoretical interest only

§8.3.1 LCSD

• Thoracoscopic dissection of lower two-thirds of left stellate ganglion + T2–T4 ganglia
• Elevates VF threshold, prolongs ventricular refractoriness, augments vagal efferent activity
• Largest multicenter series (n=63): Major cardiac events 86%→21% (p<0.001) over median 37-month follow-up; mean annual event rate 3.4 → 0.5/year (92% reduction); in persistently symptomatic patients pre-LCSD, one-third still experienced recurrent events post-LCSD
• "Triple therapy" (nadolol + flecainide + LCSD): Expert consensus now advocates as first-line strategy for patients with sentinel SCA prior to diagnosis — adds protection against the catastrophic consequence of a single missed medication dose
• Bilateral CSD (LCSD + RCSD): Considered when LCSD alone is insufficient, and as an interim step before ICD implantation in patients continuing to have appropriate ICD shocks post-LCSD
• Complications: Ptosis, Horner syndrome, harlequin flushing (post-aerobic exercise/emotional excitement), pneumothorax, neuropathic pain — infrequent and usually transient; LCSD improves quality of life in LQTS/CPVT patients who have an ICD
• Not curative: one-third of patients still experience arrhythmia recurrence; not recommended as standalone therapy

§8.3.2 ICD — Paradigm Shift

• Historical Class I → now last resort: Paradigm shift toward reserving ICD for rare cases where nadolol/propranolol + flecainide + LCSD has proven inadequate
• Proarrhythmia: ICD shocks cause catecholamine surge → adrenergic drive → further SR Ca²⁺ release → more VT → more shocks → potentially lethal electrical storm; polymorphic VT and bidirectional VT shocks fail 99%; VF shocks succeed 94%
• Meta-analysis (53 studies, 1429 patients; 35% with ICD): 40% had ≥1 appropriate shock; 21% ≥1 inappropriate shock; 20% electrical storm; 60% (7) deaths attributed to ICD-associated incessant VT
• International CPVT registry (136 patients with sentinel SCA): Adverse outcome (SCD/SCA/syncope/appropriate shock) 47% with ICD vs 15.8% without ICD (confounded: no-ICD group received higher proportion of nadolol/propranolol and more guideline-directed therapy)
• Inappropriate shocks: 20–30% of CPVT patients; 24% in registry; nearly half from AF/NSVT that self-terminate
• S-ICD: Promising in channelopathies broadly; EFFORTLESS-SICD registry (199 channelopathy patients, 5.5% CPVT): similar efficacy to transvenous, reduced inappropriate shocks compared to structural heart disease; complications from inappropriate shocks remain high
• Programming: Single VF zone at 230–300 bpm (no VT zone) — reduces inappropriate shocks for PVCs and transient bidirectional/polymorphic VT; single-chamber transvenous ICD generally adequate
• PACES guidelines: pharmacologic therapy or CSD without ICD may be considered as alternative even when aborted SCA is initial presentation (Class IIa)

§8.3.3 Catheter Ablation

• Adjunctive therapy when flecainide cannot be used; not curative
• Largest series (n=14, Japan): LV basal anterior wall and LV septal area identified as predominant triggering PVC sources (contrast to prior data suggesting RVOT predominance); ~1/3 had biventricular triggering; 90%+ non-inducibility of VT/VF acutely; ~60% syncope-free at follow-up; recurrences predominantly >1 year post-ablation
• Prior 5-patient case series (avg follow-up 71 months): 80% experienced recurrent VAs requiring ICD/external defibrillator; average 4 years from ablation to recurrence
• Beta-blockers remain mandatory post-ablation; arrhythmogenic substrate is not fully eliminated
• Post-ablation non-triggering PVC induction indicates high risk of syncope recurrence → early LCSD or ICD warranted

§8.4 Future Therapies

• AAV-mediated CASQ2 gene replacement: Wild-type CASQ2 delivery to reinstate normal Ca²⁺-induced Ca²⁺ release; most advanced CPVT gene therapy strategy
• Allele-specific RNA silencing: Reduces mutant allele expression while preserving WT; demonstrated in CASQ2-R33Q models
• CRISPR/Cas9: Precise correction of mutant RYR2 or CASQ2; RYR2-R4496C CRISPR (Pan 2023) — ~41% editing efficiency, 0/7 treated vs 7/8 controls with arrhythmias
• CaM kinase pathway modulation: Mutation-agnostic; targets beta-adrenergic signalling pathways regardless of specific mutation
• iPSC-CMs: Capacity for genotype/phenotype-guided pharmacological testing; not yet applied to CPVT studies
• Outstanding challenge: Immune responses to viral vectors and inflammatory complications in large animal models; requires technical refinement before clinical translation

Limitations of the Document

• Narrative review — no primary data generated; clinical recommendations drawn from cited literature
• MDPI open-access journal (J. Clin. Med.); no explicit conflict of interest declarations required; peer review less rigorous than ESC/HRS guideline process
• ICD outcome data from international registry is potentially confounded (ICD patients received suboptimal BB therapy vs no-ICD group)
• Management flowchart adapted from published algorithms (Priori and Roses-Noguer) — not independently developed

Key Concepts Mentioned

• concepts/Left-Cardiac-Sympathetic-Denervation — largest CPVT multicenter series (63 patients, 92% event rate reduction); triple therapy concept
• concepts/Sudden-Cardiac-Death — primary outcome; 30–50% by age 35 untreated
• concepts/Electrical-Storm — ICD shock-triggered adrenergic cascade in CPVT
• concepts/Bidirectional-Ventricular-Tachycardia — pathognomonic arrhythmia pattern
• concepts/Gene-Editing-Risk-Benefit-Framework — CRISPR/Cas9 and AAV strategies reviewed
• concepts/AAV-Gene-Delivery — CASQ2 replacement; CaMKII peptide strategies

Key Entities Mentioned

• entities/CPVT — comprehensive clinical review; Giudicessi scorecard; ICD paradigm shift; LCSD triple therapy; catheter ablation LV origin data
• entities/RYR2 — hotspot regions; de novo variant severity; penetrance; CNV analysis
• entities/Flecainide — 2–3 mg/kg/day dosing; 14-patient RCT; 247-patient multinational cohort; mechanism debate
• entities/CASQ2 — CPVT2 features; novel neurological manifestations; AAV replacement target

Wiki Pages Updated

• wiki/entities/CPVT.md — Giudicessi diagnostic scorecard; nadolol hazard ratio data; non-adherence data; BB-free strategy; LCSD triple therapy + 63-patient series; ICD paradigm shift meta-analysis + registry data + S-ICD; catheter ablation LV origin finding; ivabradine/verapamil/dantrolene negative data; updated contradictions
• wiki/concepts/Left-Cardiac-Sympathetic-Denervation.md — 63-patient multicenter CPVT series details; triple therapy; RCSD addition; complications; QoL benefit
• wiki/entities/Flecainide.md — CPVT-specific dosing and trial data (14-patient RCT; 247-patient cohort)